Literature DB >> 31919620

Inhibition of the mammalian target or rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy.

Alain Ndayisaba1, Gregor K Wenning2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31919620     DOI： 10.1007/s10286-019-00662-4

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN： 0959-9851            Impact factor:   4.435


× No keyword cloud information.
  12 in total

1.  Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway.

Authors:  Jochen Klucken; Anne-Maria Poehler; Darius Ebrahimi-Fakhari; Jacqueline Schneider; Silke Nuber; Edward Rockenstein; Ursula Schlötzer-Schrehardt; Bradley T Hyman; Pamela J McLean; Eliezer Masliah; Juergen Winkler
Journal:  Autophagy       Date:  2012-05-01       Impact factor: 16.016

2.  Insulin resistance and exendin-4 treatment for multiple system atrophy.

Authors:  Fares Bassil; Marie-Hélène Canron; Anne Vital; Erwan Bezard; Yazhou Li; Nigel H Greig; Seema Gulyani; Dimitrios Kapogiannis; Pierre-Olivier Fernagut; Wassilios G Meissner
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

3.  Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system.

Authors:  Maria Teresa Pellecchia; Rosario Pivonello; Katia Longo; Michela Manfredi; Alessandro Tessitore; Marianna Amboni; Claudia Pivonello; Mariangela Rocco; Autilia Cozzolino; Annamaria Colao; Paolo Barone
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 4.  Management of Leigh syndrome: Current status and new insights.

Authors:  L Chen; Y Cui; D Jiang; C Y Ma; H-F Tse; W-L Hwu; Q Lian
Journal:  Clin Genet       Date:  2018-02-11       Impact factor: 4.438

5.  A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.

Authors:  Ellen Kraig; Leslie A Linehan; Hanyu Liang; Terry Q Romo; Qianqian Liu; Yubo Wu; Adriana D Benavides; Tyler J Curiel; Martin A Javors; Nicolas Musi; Laura Chiodo; Wouter Koek; Jonathan A L Gelfond; Dean L Kellogg
Journal:  Exp Gerontol       Date:  2018-02-03       Impact factor: 4.032

6.  mTOR inhibition improves immune function in the elderly.

Authors:  Joan B Mannick; Giuseppe Del Giudice; Maria Lattanzi; Nicholas M Valiante; Jens Praestgaard; Baisong Huang; Michael A Lonetto; Holden T Maecker; John Kovarik; Simon Carson; David J Glass; Lloyd B Klickstein
Journal:  Sci Transl Med       Date:  2014-12-24       Impact factor: 17.956

Review 7.  Fighting neurodegeneration with rapamycin: mechanistic insights.

Authors:  Jordi Bové; Marta Martínez-Vicente; Miquel Vila
Journal:  Nat Rev Neurosci       Date:  2011-07-20       Impact factor: 34.870

Review 8.  It may be possible to delay the onset of neurodegenerative diseases with an immunosuppressive drug (rapamycin).

Authors:  Ester Aso; Isidre Ferrer
Journal:  Expert Opin Biol Ther       Date:  2013-05-14       Impact factor: 4.388

9.  Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived α-synuclein in oligodendroglia: implications for MSA pathogenesis.

Authors:  Lisa Fellner; Edith Buchinger; Dominik Brueck; Regina Irschick; Gregor K Wenning; Nadia Stefanova
Journal:  BMC Neurosci       Date:  2018-05-21       Impact factor: 3.288

Review 10.  Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives.

Authors:  Giacomo Monzio Compagnoni; Alessio Di Fonzo
Journal:  Acta Neuropathol Commun       Date:  2019-07-12       Impact factor: 7.801
View more
  1 in total

Review 1.  Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?

Authors:  Victoria Sidoroff; Pam Bower; Nadia Stefanova; Alessandra Fanciulli; Iva Stankovic; Werner Poewe; Klaus Seppi; Gregor K Wenning; Florian Krismer
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.